Research graph
References from Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3322/caac.20107
10.3322/caac.20107 · External reference
10.1056/nejmoa0708857
10.1056/nejmoa0708857 · External reference
10.1016/s1470-2045(08)70285-7
10.1016/s1470-2045(08)70285-7 · External reference
10.1158/1078-0432.ccr-09-2084
10.1158/1078-0432.ccr-09-2084 · External reference
10.1002/hep.26586
10.1002/hep.26586 · External reference
10.1200/jco.2012.47.3009
10.1200/jco.2012.47.3009 · External reference
Unresolved reference
2012 · External reference
Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).
2012 · External reference
10.1200/jco.2012.45.8372
10.1200/jco.2012.45.8372 · External reference
10.1200/jco.2012.48.4410
10.1200/jco.2012.48.4410 · External reference
10.1038/nrc3205
10.1038/nrc3205 · External reference
10.1002/hep.24450
10.1002/hep.24450 · External reference
10.1016/s1535-6108(03)00085-0
10.1016/s1535-6108(03)00085-0 · External reference
10.1158/1078-0432.ccr-12-1281
10.1158/1078-0432.ccr-12-1281 · External reference
10.1158/0008-5472.can-10-0489
10.1158/0008-5472.can-10-0489 · External reference
10.1016/s1470-2045(12)70490-4
10.1016/s1470-2045(12)70490-4 · External reference
10.1200/jco.2010.34.0570
10.1200/jco.2010.34.0570 · External reference
Unresolved reference
2012 · External reference
10.1158/1535-7163.mct-09-1173
10.1158/1535-7163.mct-09-1173 · External reference
Unresolved reference
2009 · External reference
Unresolved reference
2007 · External reference
10.1158/1078-0432.ccr-12-3459
10.1158/1078-0432.ccr-12-3459 · External reference
10.1158/0008-5472.can-12-3256
10.1158/0008-5472.can-12-3256 · External reference
Unresolved reference
2013 · External reference
The novel c-MET inhibitor, ARQ 197, shows additive growth-inhibitory effect with erlotinib through enhanced degradation of c-MET protein via ubiquitin/proteasome pathway.
2010 · External reference
10.1158/1535-7163.mct-13-0187
10.1158/1535-7163.mct-13-0187 · External reference
10.1021/cb400660a
10.1021/cb400660a · External reference
10.1200/jco.2010.31.0367
10.1200/jco.2010.31.0367 · External reference
10.1158/1078-0432.ccr-13-1321
10.1158/1078-0432.ccr-13-1321 · External reference
MET inhibitor tivantinib (ARQ 197) plus erlotinib vs erlotinib plus placebo in NSCLC.
2013 · External reference
10.1200/jco.2013.31.15_suppl.3508
10.1200/jco.2013.31.15_suppl.3508 · External reference
10.1038/bjc.2012.556
10.1038/bjc.2012.556 · External reference
10.1200/jco.2012.30.15_suppl.4117
10.1200/jco.2012.30.15_suppl.4117 · External reference
MET as prognostic factor and therapeutic target in pretreated hepatocellular carcinoma (HCC): final results of a randomized controlled Phase 2 trial (RCT) with tivantinib (ARQ 197).
2012 · External reference
Unresolved reference
External reference
